Profile data is unavailable for this security.
About the company
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.63m
- Incorporated2021
- Employees5.00
- LocationGenflow Biosciences PLC15 Ingestre PlaceLONDON W1F 0DUUnited KingdomGBR
- Websitehttps://genflowbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSF Enterprise PLC | 67.24k | -1.71m | 5.94m | 4.00 | -- | 1.49 | -- | 88.37 | -0.0166 | -0.0166 | 0.0007 | 0.0387 | 0.0128 | 1.79 | 0.0425 | 16,810.00 | -32.47 | -- | -34.78 | -- | -44.74 | -- | -2,542.56 | -- | 6.17 | -218.85 | 0.0287 | -- | -- | -- | -61.40 | -- | -- | -- |
| Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 9.04m | 91.00 | -- | 0.9719 | -- | 0.9996 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
| Kanabo Group PLC | 895.00k | -7.99m | 9.17m | 20.00 | -- | 1.22 | -- | 10.25 | -0.0137 | -0.0137 | 0.0017 | 0.0119 | 0.0785 | 11.11 | 28.41 | -- | -70.12 | -75.83 | -77.61 | -83.33 | 14.97 | -- | -893.30 | -1,267.35 | 4.96 | -10.43 | 0.035 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -2.92m | 9.29m | 5.00 | -- | 8.79 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.55m | 10.11m | 10.00 | -- | 2.86 | -- | -- | -0.0351 | -0.0351 | 0.00 | 0.0429 | 0.00 | -- | -- | -- | -57.64 | -- | -65.12 | -- | -- | -- | -- | -- | -- | -- | 0.069 | -- | -- | -- | -1.92 | -- | -- | -- |
| Destiny Pharma PLC | 0.00 | -5.66m | 10.51m | 19.00 | -- | 1.14 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | 0.00 | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.02 | -- | 35.39 | -- |
| Oncimmune Holdings PLC | 1.21m | -3.19m | 10.64m | 56.00 | -- | -- | -- | 8.76 | -0.0427 | 0.0939 | 0.0163 | -0.0172 | 0.1756 | 1.19 | 0.6917 | -- | -46.21 | -- | -- | -- | 63.34 | -- | -263.10 | -- | 1.01 | -0.6815 | 1.32 | -- | -- | -- | -- | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.63m | 10.84m | 5.00 | -- | 12.49 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 10.89m | 2.00 | -- | -- | -- | 74.24 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Synairgen plc | 0.00 | -9.99m | 11.66m | 30.00 | -- | 0.7304 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| Proteome Sciences plc | 5.03m | -2.44m | 12.43m | 35.00 | -- | -- | -- | 2.47 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Genincode PLC | 2.16m | -7.02m | 12.61m | 36.00 | -- | 5.30 | -- | 5.84 | -0.0732 | -0.0732 | 0.0225 | 0.0135 | 0.2703 | 21.88 | 3.33 | 60,000.00 | -87.79 | -- | -124.10 | -- | 47.31 | -- | -324.81 | -- | 1.24 | -- | 0.1883 | -- | 51.05 | -- | -26.21 | -- | -- | -- |
| Provexis plc | 598.08k | -496.59k | 14.14m | 2.00 | -- | 14.10 | -- | 23.65 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 14.19m | 82.00 | -- | 7.52 | -- | 2.66 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| LungLife AI Inc | 36.27k | -4.27m | 14.50m | 15.00 | -- | 0.6986 | -- | 399.68 | -0.1675 | -0.1675 | 0.0014 | 0.2448 | 0.0038 | -- | 0.2831 | 2,418.13 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Genflow Biosciences PLC's reporting currency: UK Pound GBX
9.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 09 Apr 2024 | 32.00m | 9.15% |
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
